相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Immunology
Harika Oyku Dinc et al.
Summary: Healthcare workers were among the first groups to be vaccinated in Turkey, and two doses of CoronaVac vaccine produced effective humoral immunity in HCWs. The antibody response was significantly higher in those with a prior history of COVID-19, suggesting that a single shot of vaccination may be sufficient for this group.
Article
Immunology
Chunfeng Li et al.
Summary: The BNT162b2 mRNA vaccine stimulates potent antibody and antigen-specific T cell responses, as well as enhanced innate responses after secondary immunization. Circulating IFN-gamma is mainly produced by natural killer cells and CD8(+) T cells in the draining lymph nodes. The CD8(+) T cell response is dependent on type I interferon-dependent MDA5 signaling.
Article
Multidisciplinary Sciences
Bruna Lo Sasso et al.
Summary: Assessing anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third dose of the SARS-CoV-2 vaccine induces a strong immunological response, supporting the efficacy of the vaccine programs and the usefulness of the third dose.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Lu Lu et al.
Summary: The study showed that in recovered COVID-19 patients, recipients of the BNT162b2 vaccine had significantly higher serum Omicron neutralizing antibody titers compared to non-vaccinated individuals. Additionally, receiving two doses of CoronaVac was more effective in inducing detectable serum Omicron antibodies than one dose.
Article
Immunology
Zsolt Matula et al.
Summary: The study compared the immune responses elicited by BBIBP-CorV and BNT162b2 vaccines after 6 months of immunization. It was found that the T cell responses were similar, but there were differences in humoral immunity. Administering a third dose of BNT162b2 after BBIBP-CorV significantly enhanced the immune response.
Article
Immunology
Jose Tuells et al.
Summary: This study investigated the presence of neutralizing antibodies against SARS-CoV-2 among healthcare workers in a hospital in Alicante, Spain, and compared the efficiency of a rapid diagnostic test to an ELISA viral neutralization test. The rapid test demonstrated high specificity and sensitivity, and individuals immunized with the BioNTech/Pfizer vaccine maintained optimal levels of neutralizing antibodies after six months. The use of this rapid test could be a potential tool in population-based studies to detect antibody responses to vaccination and guide vaccination policies for high-risk populations.
Article
Immunology
Konstantina Kontopoulou et al.
Summary: The aim of the study was to assess the immunogenicity of the third dose of the BNT162b2 mRNA COVID-19 vaccine in 129 healthcare workers in Greece. The study found that the third dose significantly increased antibody levels and elicited a stronger immune response compared to the second dose.
Article
Immunology
Irene Cassaniti et al.
Summary: This study investigated the role of a third dose of the BNT162b2 vaccine in kidney transplant recipients. The researchers found an increased immune response, especially in terms of T cell response to the Spike protein, after the third dose. However, the seroconversion rate remained below 50%. Mycophenolate treatment, steroid administration, and age appeared to be associated with a poor immune response.
Letter
Medicine, General & Internal
Noa Eliakim-Raz et al.
Summary: This study focuses on evaluating the anti-S IgG antibody levels before and after the administration of a third dose of the BNT162b2 vaccine in individuals aged 60 and older in Israel.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Editorial Material
Hematology
Rabah Redjoul et al.
LANCET HAEMATOLOGY
(2021)
Article
Immunology
Gisella Guerrera et al.
Summary: Vaccination with the Pfizer-BioNTech mRNA vaccine induces a sustained anti-viral T cell response for at least 6 months, demonstrating immunological competence and long-term memory against SARS-CoV-2.
SCIENCE IMMUNOLOGY
(2021)
Article
Immunology
Edrous Alamer et al.
Summary: This study aimed to investigate the early side effects of the Pfizer-BioNTech (BNT162b2) mRNA vaccine in children aged 12-18 years in Saudi Arabia. Results showed that 60% of the participants reported at least one side effect, with pain or redness at the injection site, fatigue, fever, and headache being the most frequently reported. Female participants reported side effects more frequently than male participants, and side effects were more common after the second dose of the vaccine.
Letter
Medicine, General & Internal
Ann R. Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Amelia E. Sancilio et al.
Summary: The immunoassay-based method validated in this study can quantify neutralization of the spike-ACE2 interaction in a single drop of capillary whole blood collected as dried blood spot samples. This scalable and minimally invasive alternative to venous blood collection offers a practical way to measure neutralizing antibodies and estimate immunity levels against COVID-19 in the general population.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Bruna Lo Sasso et al.
Summary: The study demonstrates an effective antibody response post-vaccination, with variations in antibody levels among different vaccinated groups, and higher antibody levels observed in females.
Article
Cell Biology
Alison Tarke et al.
Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.
CELL REPORTS MEDICINE
(2021)
